Dyspepsia Market Report and Forecast 2024-2032

Dyspepsia Market Report and Forecast 2024-2032


Dyspepsia Market Report and Forecast 2024-2032

Dyspepsia Market Outlook

The dyspepsia market size is anticipated to grow at a CAGR of 8.4% during the forecast period of 2024-2032, driven by the growing emphasis on personalized or precision medicine in disease management across the major markets.

Dyspepsia: Introduction

Dyspepsia, commonly known as indigestion, is a condition characterized by chronic or recurrent discomfort in the upper abdomen. Symptoms may include bloating, nausea, belching, and a feeling of fullness or pain after eating. Dyspepsia can result from various causes, including gastritis, peptic ulcers, gastroesophageal reflux disease (GERD), or functional (non-ulcer) dyspepsia, where no clear cause is found. Management typically involves lifestyle modifications, dietary changes, and medications such as antacids, proton pump inhibitors, or H2-receptor antagonists to relieve symptoms.

Key Trends in the Dyspepsia Market

There's a growing trend towards increased awareness of dyspepsia symptoms and self-management practices. Over-the-counter (OTC) medications for symptom relief are in high demand, with consumers seeking immediate and accessible remedies.

As the understanding of the impact of lifestyle and diet on dyspepsia grows, there's a noticeable shift towards non-pharmacological interventions. This includes dietary modifications, stress reduction techniques, and lifestyle changes as first-line management strategies.

The market is gradually moving towards personalized treatment approaches in managing dyspepsia, especially for cases related to specific underlying conditions like H. pylori infection, GERD, or peptic ulcer disease. This trend is driven by advancements in diagnostic technologies and a better understanding of the pathophysiology of dyspepsia.

There's ongoing research and development of new pharmaceuticals targeting the underlying causes of dyspepsia and improving symptom management. This includes the development of drugs with novel mechanisms of action, such as prokinetics and agents that target the gut-brain axis.

Integration of Digital Health Solutions: Digital health technologies, including apps for diet tracking and stress management, are becoming more integrated into the management of dyspepsia. These tools help patients monitor their symptoms, manage their condition more effectively, and adhere to treatment plans.

Emerging research on the gut microbiome's role in various gastrointestinal disorders, including dyspepsia, is influencing treatment approaches. Probiotics and dietary supplements aimed at restoring gut microbiome balance are gaining popularity as complementary therapies.

Dyspepsia Market Segmentation

Market Breakup by Diagnosis
  • Blood Tests
  • Stool Tests
  • Breath Tests
  • Endoscopy
  • X-Ray
  • CT Scan
  • Others
Market Breakup by Type
  • Organic Dyspepsia
  • Non-Ulcer Dyspepsia
  • Drug Induced Dyspepsia
  • Others
Market Breakup by Indication
  • Functional Dyspepsia
  • Organic Dyspepsia
Market Breakup by Treatment
  • Proton Pump Inhibitors
  • H2 Blockers
  • Antacids
  • Antibiotics
  • Prokinetics
  • Antidepressants
Market Breakup by Treatment Type
  • Medication
  • Surgery
Market Breakup by Drug Type
  • Branded
  • Generic
Market Breakup by Route of Administration
  • Oral
  • Injectable
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • China
Dyspepsia Market Overview

In North America, the dyspepsia market is driven by a high prevalence of gastrointestinal disorders and a significant focus on digestive health. Lifestyle factors and dietary habits contribute to the demand for treatment options. The market includes a wide range of over-the-counter (OTC) and prescription medications, alongside a growing interest in probiotics and dietary supplements for symptom management. There's also an emphasis on personalized treatment approaches and non-pharmacological interventions, such as dietary modifications and stress management techniques.

Europe's market is characterized by strong healthcare systems and an emphasis on evidence-based treatments for dyspepsia. Public health initiatives aimed at improving dietary habits and reducing alcohol and tobacco consumption impact market dynamics. The availability of OTC medications is high, and there's a notable interest in natural and alternative remedies. Regulatory frameworks support rigorous testing and approval processes for new treatments, ensuring patient safety and treatment efficacy.

In Japan, the dyspepsia market reflects the country's high regard for gastrointestinal health, with a wide acceptance of both modern and traditional treatments. Japanese consumers show a strong preference for products with natural ingredients and traditional medicines alongside conventional treatments. The market is supported by advanced healthcare research, leading to the development of innovative therapeutics. Public health campaigns focusing on healthy eating and lifestyle habits also play a crucial role in managing dyspepsia symptoms.

Dyspepsia Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Bayer AG
  • Mankind Pharma
  • Cadila Pharmaceuticals
  • Salix Pharmaceuticals
  • Sanofi
  • Aosaikand Pharmaceutical Co., Ltd
  • Hanmi Pharm. Co.
  • Lupin
  • RedHill Biopharma Ltd.
  • Abbott.
  • GlaxoSmithKline
  • Johnson&Johnson
  • Eisai Co Ltd
  • AstraZeneca
  • Allergen Plc
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Dyspepsia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Drug
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Dyspepsia Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Dyspepsia Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Dyspepsia Epidemiology Forecast (2017-2032)
5.3.1 Germany Dyspepsia Epidemiology Forecast (2017-2032)
5.3.2 France Dyspepsia Epidemiology Forecast (2017-2032)
5.3.3 Italy Dyspepsia Epidemiology Forecast (2017-2032)
5.3.4 Spain Dyspepsia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Dyspepsia Epidemiology Forecast (2017-2032)
5.4 Japan Dyspepsia Epidemiology Forecast (2017-2032)
6 Dyspepsia Market Overview – 7MM
6.1 Dyspepsia Market Historical Value (2017-2023)
6.2 Dyspepsia Market Forecast Value (2024-2032)
7 Dyspepsia Market Landscape – 7MM
7.1 Dyspepsia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Dyspepsia Product Landscape
7.2.1 Analysis by Indication
7.2.2 Analysis by Drug Type
8 Dyspepsia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Dyspepsia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Dyspepsia Market Segmentation – 7MM
11.1 Dyspepsia Market by Diagnosis
11.1.1 Market Overview
11.1.2 Blood Tests
11.1.3 Stool Tests
11.1.4 Breath Tests
11.1.5 Endoscopy
11.1.6 X-Ray
11.1.7 CT Scan
11.1.8 Others
11.2 Dyspepsia Market by Type
11.2.1 Market Overview
11.2.2 Organic Dyspepsia
11.2.3 Non-Ulcer Dyspepsia
11.2.4 Drug Induced Dyspepsia
11.2.5 Others
11.3 Dyspepsia Market by Indication
11.3.1 Market Overview
11.3.2 Functional Dyspepsia
11.3.3 Organic Dyspepsia
11.4 Dyspepsia Market by Treatment
11.4.1 Market Overview
11.4.2 Proton Pump Inhibitors
11.4.3 H2 Blockers
11.4.4 Antacids
11.4.5 Antibiotics
11.4.6 Prokinetics
11.4.7 Antidepressants
11.5 Dyspepsia Market by Treatment Type
11.5.1 Market Overview
11.5.2 Medication
11.5.3 Surgery
11.6 Dyspepsia Market by Drug Type
11.6.1 Market Overview
11.6.2 Branded
11.6.3 Generic
11.7 Dyspepsia Market by Route of Administration
11.7.1 Market Overview
11.7.2 Oral
11.7.3 Injectable
11.8 Dyspepsia Market by Region
11.8.1 Market Overview
11.8.2 United States
11.8.3 EU-4 and the United Kingdom
11.8.3.1 Germany
11.8.3.2 France
11.8.3.3 Italy
11.8.3.4 Spain
11.8.3.5 United Kingdom
11.8.4 Japan
12 United States Dyspepsia Market
12.1 Dyspepsia Market Historical Value (2017-2023)
12.2 Dyspepsia Market Forecast Value (2024-2032)
12.3 Dyspepsia Market by Diagnosis
12.4 Dyspepsia Market by Indication
13 EU-4 and United Kingdom Dyspepsia Market
13.1 Dyspepsia Market Historical Value (2017-2023)
13.2 Dyspepsia Market Forecast Value (2024-2032)
13.3 Germany Dyspepsia Market Overview
13.3.1 Dyspepsia Market by Diagnosis
13.3.2 Dyspepsia Market by Indication
13.4 France Dyspepsia Market Overview
13.4.1 Dyspepsia Market by Diagnosis
13.4.2 Dyspepsia Market by Indication
13.5 Italy Dyspepsia Market Overview
13.5.1 Dyspepsia Market by Diagnosis
13.5.2 Dyspepsia Market by Indication
13.6 Spain Dyspepsia Market Overview
13.6.1 Dyspepsia Market by Diagnosis
13.6.2 Dyspepsia Market by Indication
13.7 United Kingdom Dyspepsia Market Overview
13.7.1 Dyspepsia Market by Diagnosis
13.7.2 Dyspepsia Market by Indication
14 Japan Dyspepsia Market
14.1 Dyspepsia Market Historical Value (2017-2023)
14.2 Dyspepsia Market Forecast Value (2024-2032)
14.3 Dyspepsia Market by Diagnosis
14.4 Dyspepsia Market by Indication
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Bayer AG
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Mankind Pharma
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Cadila Pharmaceuticals
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Salix Pharmaceuticals
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Sanofi
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Aosaikand Pharmaceutical Co., Ltd
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Hanmi Pharm. Co.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Lupin
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 RedHill Biopharma Ltd.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Abbott.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 GlaxoSmithKline
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Johnson & Johnson
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Eisai Co Ltd
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 AstraZeneca
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Allergen Plc
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Dyspepsia Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings